These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3300097)

  • 1. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Liver damage in hormone therapy of prostate cancer].
    Zade W; Schott H
    Z Urol Nephrol; 1987 Mar; 80(3):177-9. PubMed ID: 3604474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of ethinyl estradiol sulfonate (Turisteron)--long-term results of a randomized compound study].
    Böhm WD; Gorski J; Geissler W; Illig HD; Koch R
    Z Urol Nephrol; 1987 Mar; 80(3):159-64. PubMed ID: 2440199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibition of the free, biologically active testosterone level by Turisteron in patients with prostate cancer].
    Stahl F; Schnorr D; Rohde W; Dörner G
    Z Urol Nephrol; 1987 Mar; 80(3):135-8. PubMed ID: 3604472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
    Benson RC; Cummings K
    Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
    [No Abstract]   [Full Text] [Related]  

  • 6. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J
    Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
    [No Abstract]   [Full Text] [Related]  

  • 7. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience using Turisteron in the treatment of prostatic cancer].
    Sladczyk E
    Z Urol Nephrol; 1987 Mar; 80(3):181-3. PubMed ID: 3604475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Initial results of a phase IV multicenter clinical trial of Turisteron in the treatment of prostate cancer].
    Guddat HM; Schnorr D; Zemke F
    Z Urol Nephrol; 1987 Mar; 80(3):165-70. PubMed ID: 3300098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Conservative therapy of prostate cancer using Turisteron].
    Schnorr D; Dörner G; Stahl F; Rohde W; Guddat HM
    Z Urol Nephrol; 1987 Mar; 80(3):149-57. PubMed ID: 3111122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EORTC Phase III trials in prostatic cancer.
    Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
    Daponte DP; Stevens I; Robinson MR
    Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644
    [No Abstract]   [Full Text] [Related]  

  • 15. Estramustine for prostate cancer.
    Med Lett Drugs Ther; 1982 Aug; 24(615):74. PubMed ID: 7099111
    [No Abstract]   [Full Text] [Related]  

  • 16. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
    Németh A; Morvay J; Vécsei B
    Orv Hetil; 1981 Apr; 122(17):1017-20. PubMed ID: 7022313
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)].
    Stridsklev IC; Fosså SD; Kaalhus O
    Tidsskr Nor Laegeforen; 1984 Oct; 104(28):1977-80. PubMed ID: 6388019
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC; Gill GM; Cummings KB
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experiences in the treatment of advanced prostatic cancer using Turisteron with special reference to cardiovascular complications].
    Drawz B; Hoffmann L; Drawz G; Russbüldt R
    Z Urol Nephrol; 1987 Mar; 80(3):171-5. PubMed ID: 3604473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
    Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.